Compare Salesforce Inc (CRM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Sana Biotechnology Inc — how do they compare? Salesforce Inc trades at $192.95 (market cap $161.73B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Salesforce Inc is far larger — about 143.1× Sana Biotechnology Inc's market cap, and Salesforce Inc pays a 0.89% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| CRM | SANA | |
|---|---|---|
Market Cap | $161.73B | $1.13B |
Sector | Technology | Health |
52-Week High | $266.23 | $5.92 |
52-Week Low | $150.12 | $2.68 |
Enterprise Value | $191.77B | $1.05B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.47, showing minimal daily movement (-0.02%) amid recent market volatility. The stock maintains strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show bullish momentum with support at $196 and resistance at $199, though RSI levels suggest potential overbought conditions. Recent news highlights AI-driven growth opportunities but also sector-wide software stock pressures.
CRM presents a compelling investment case with analyst consensus pointing to 17% upside to the $230.83 price target. Strong cash flow generation ($13.09B operating cash flow) and AI monetization progress support growth, but risks include competitive AI landscape and macroeconomic sensitivity affecting software demand. Institutional sentiment remains positive with 75.78% buy ratings.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
